Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 17 January 2026 - 20 January 2026

Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead Sciences shares slipped 0.2% to $124.68 Tuesday, outperforming a broader market drop. Bernstein reiterated its Outperform rating and $135 target, citing Yeztugo as a key 2026 driver. Florida announced steep cuts to its AIDS Drug Assistance Program, drawing criticism from advocates and raising concerns over HIV drug access.
20 January 2026
··
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck shares traded near $108.82 Tuesday after Merck and Moderna reported their personalized melanoma vaccine with Keytruda cut recurrence or death risk by 49% over five years in a phase 2b trial. The stock showed little change following the update. More data will be presented at a future medical meeting. Investors await Merck’s Feb. 3 earnings call for further details on its oncology portfolio.
20 January 2026
····
AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates

AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates

AstraZeneca shares fell 4.4% to $90.23 Tuesday after the company said it will delist its American depositary shares from Nasdaq and move to a direct listing of ordinary shares on the NYSE starting February 2. The switch, set for after markets close January 30, comes as European stocks face pressure from U.S. tariff threats. AstraZeneca’s London shares also dropped 2.6%.
20 January 2026
···
Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

Eli Lilly shares rose about 0.2% Tuesday after the FDA granted Breakthrough Therapy designation to its experimental ovarian cancer drug, sofetabart mipitecan. The stock traded near $1,040 as the broader market fell 1%. The designation covers patients with platinum-resistant disease who have tried other therapies. Bernstein maintained its Outperform rating and $1,300 price target.
20 January 2026
··
RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT Therapeutics shares soared 64% to $57.54 after GSK announced a $58-per-share cash acquisition, valuing the biotech at $2.2 billion. The deal centers on ozureprubart, an experimental anti-IgE drug for food allergies. GSK plans to launch a tender offer within 10 business days, pending antitrust review. RAPT’s stock hovered just below the offer price as investors watched for regulatory developments.
20 January 2026
···
Novo Nordisk stock drops in Copenhagen as Wegovy pill demand gets its first real test

Novo Nordisk stock drops in Copenhagen as Wegovy pill demand gets its first real test

Novo Nordisk B shares fell 2.8% Monday in Copenhagen, closing at 378.15 crowns as investors reacted to early U.S. prescription data for the new oral form of Wegovy. Around 4.7 million shares traded. U.S. prescriptions for oral Wegovy reached nearly 3,100 for the week ending Jan. 9, while overall Wegovy prescriptions dropped 11%. Full-year results are due Feb. 4.
19 January 2026
··
AstraZeneca share price slips in London as tariff threat rattles markets; EMA review and earnings in focus

AstraZeneca share price slips in London as tariff threat rattles markets; EMA review and earnings in focus

AstraZeneca shares fell 1.15% to 13,890 pence in London as markets reacted to President Trump’s threat of new U.S. tariffs on Britain and other European countries. The FTSE 100 closed down 0.4%. AstraZeneca announced EU validation for Enhertu and a $630 million buyout of China cell-therapy rights. Investors trimmed risk ahead of possible trade retaliation.
19 January 2026
···
Roche stock price slips in Zurich as tariff shock shakes markets — what investors watch next

Roche stock price slips in Zurich as tariff shock shakes markets — what investors watch next

Roche Holding’s non-voting equity securities fell 0.6% to 346.80 francs Monday, just below their one-year high. The drop followed global stock declines after U.S. President Donald Trump threatened tariffs on eight European nations. Investors shifted into the Swiss franc and yen. Roche will report full-year 2025 results on Jan. 29 before the market opens.
19 January 2026
··
Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly shares rose 0.5% to $1,038.40 Friday, ahead of a holiday-shortened week. Traders are watching early U.S. prescription numbers for Novo Nordisk’s new oral Wegovy, which logged 3,071 scripts in its debut, just below Lilly’s Zepbound. U.S. markets reopen Tuesday, with investors eyeing fresh demand signals and pricing risks. About 3.8 million Lilly shares traded Friday.
19 January 2026
···
Novartis stock price: NOVN ends higher on FDA Breakthrough tag for Sjögren’s drug ianalumab — what to watch next week

Novartis stock price: NOVN ends higher on FDA Breakthrough tag for Sjögren’s drug ianalumab — what to watch next week

Novartis shares closed up nearly 1% at 115.60 francs in Zurich after U.S. regulators granted Breakthrough Therapy status to its Sjögren’s disease drug candidate, ianalumab. The Swiss Market Index fell 0.47%. Novartis plans global submissions for ianalumab in early 2026. U.S. markets will be closed Monday for Martin Luther King Jr. Day.
18 January 2026
··
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie shares fell 1.1% to $214.35 Friday after partner Genmab said their blood cancer drug epcoritamab failed to meet the main survival goal in a Phase 3 trial. Genmab’s U.S. shares dropped over 7%. AbbVie reported a benefit for progression-free survival but not overall survival. Investors await AbbVie’s earnings report on Feb. 4.
18 January 2026
····
Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Novo Nordisk shares surged 6.49% to 388.90 Danish crowns Friday after early U.S. prescription data for its new Wegovy pill and UK approval of a higher Wegovy dose. U.S. retail pharmacies filled 3,071 Wegovy pill prescriptions in the first four days, not counting online sales. Novo’s ADRs rose 0.74% in New York. Investors await the company’s earnings report on Feb. 4.
18 January 2026
·
Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

Pfizer shares fell 0.93% to $25.65 Friday amid industry concerns over a White House-backed fast FDA review program, Reuters reported. The company reaffirmed its 2026 revenue forecast and set its next dividend at $0.43 per share, with an ex-dividend date of Jan. 23. U.S. markets will close Monday for Martin Luther King Jr. Day. Pfizer’s quarterly results are due Feb. 3.
18 January 2026
··
Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Novo Nordisk A/S Class B shares surged 6.5% to 388.9 Danish crowns Friday in Copenhagen after early U.S. prescription data for the new Wegovy pill surfaced and Britain approved a higher Wegovy dose for certain obesity patients. Trading volume reached 13.9 million shares. IQVIA data showed 3,071 U.S. retail prescriptions for the pill in its first four days, not counting online orders.
17 January 2026
··
1 … 6 7 8 9 10 … 34

Stock Market Today

Oil stocks jump on Iran risk lift for crude — what to watch before Monday

Oil stocks jump on Iran risk lift for crude — what to watch before Monday

7 February 2026
U.S. oil stocks surged Friday as crude prices rose on renewed Middle East tensions. Exxon Mobil gained 2.0%, ConocoPhillips 2.5%, and Occidental Petroleum 2.7%. Refiners rallied after a national union deal eased strike risk, though BP’s Whiting plant faces a local dispute. Brent settled at $68.05 a barrel, up 0.74%.
Silver price rebound masks fresh stress after CME lifts margins again

Silver price rebound masks fresh stress after CME lifts margins again

7 February 2026
Spot silver surged 8.6% to $77.33 an ounce Friday after dropping below $65, but still lost over 8.7% for the week. CME Group raised margin requirements for COMEX silver futures to 18% from 15%, effective after Feb. 6. China’s UBS SDIC Silver Futures Fund hit its 10% down limit for a fifth session. Traders await key U.S. jobs and inflation data next week.
Gold price near $5,000: China keeps buying as CME margin hikes raise the stakes

Gold price near $5,000: China keeps buying as CME margin hikes raise the stakes

7 February 2026
China’s central bank raised gold reserves for a 15th month in January, reaching 74.19 million ounces worth $369.58 billion. Gold prices swung sharply, hitting a record near $5,600 before dropping to $4,403.24. CME Group hiked COMEX gold futures margins to 9% after recent volatility. U.S. jobs and inflation data are due next week after a delay.
Amazon stock (AMZN) slides on $200 billion AI capex plan — what Wall Street watches next week

Amazon stock (AMZN) slides on $200 billion AI capex plan — what Wall Street watches next week

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company forecast 2026 capital spending would jump to $200 billion, up more than 50% from 2025. The drop came as the Dow closed above 50,000 for the first time. Amazon reported fourth-quarter net sales up 14% to $213.4 billion and operating income at $25 billion. Trading in Amazon was volatile, with 179 million shares changing hands.
Go toTop